Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study

BMC Nephrol. 2019 Mar 5;20(1):81. doi: 10.1186/s12882-019-1251-z.


Background: DOPPS reported that thousands of life-years could be gained in the US and Europe over 5 years by correcting six modifiable haemodialysis practices. We estimated potential life-years gained across 10 European countries using MONITOR-CKD5 study data.

Methods: The DOPPS-based target ranges were used, except for haemoglobin due to label changes, as well as DOPPS-derived relative mortality risks. Percentages of MONITOR-CKD5 patients outside targets were calculated. Consistent with the DOPPS-based analyses, we extrapolated life-years gained for the MONITOR-CKD5 population over 5 years if all patients were within targets.

Results: Bringing the 10 MONITOR-CKD5 countries' dialysis populations into compliance on the six practices results in a 5-year gain of 97,428 patient-years. In descending order, survival impact was the highest for albumin levels, followed by phosphate levels, vascular access, haemoglobin, dialysis adequacy, and interdialytic weight gain.

Conclusions: Optimal management of the six modifiable haemodialysis practices may achieve 6.2% increase in 5-year survival.

Trial registration: NCT01121237 . Clinicaltrials.gov registration May 12, 2010 (retrospectively registered).

Keywords: Anaemia; Biosimilar epoetin alfa; Haemodialysis; Life-years; Modifiable haemodialysis practices.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Europe / epidemiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Quality-Adjusted Life Years*
  • Renal Dialysis / trends*
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / epidemiology*
  • Renal Insufficiency, Chronic / therapy*
  • Treatment Outcome
  • Young Adult

Associated data

  • ClinicalTrials.gov/NCT01121237